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Approximately 13% of the newly diagnosed tuberculosis
(TB) cases, or 1.1 million people worldwide, are co-
infected with the HIV. In 2011 alone, HIV-associated
TB contributed to over 430 000 deaths, the majority of
which were in sub-Saharan Africa [1]. The WHO has
recommended enhanced HIV and TB program collab-
oration and service integration to facilitate the concerted
prevention, treatment and support of these commonly
occurring co-infections, and mitigate their dual impact.
The principle of ‘two diseases, one patient’, however,
remains unrealized within many high-burden countries as
a result of significant challenges associated with co-
diagnosis, co-treatment and TB infection control, as well
as financial and human resource constraints [2–4]. We call
attention to the distinct paradigms underlying HIV and
TB service delivery, or the distinct ‘cultures’ of HIV and
TB care, as an additional consideration to integration
efforts.Discussion
Historically, TB control has been based in a traditional
public health approach [3,5,6]. Since the 1990s,
prevention and treatment measures have been standar-
dized under the WHO DOTS strategy. Whereas this
framework brings together critical tenets of infectious
disease control – political commitment, case detection,ippincott Williams & Wilkins. Unaut
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ing and evaluation – it emphasizes the direct observation
of treatment intake or DOT [7]. The emerging challenges
of HIV and drug-resistant TB have prompted several
modifications to this framework, including greater
community involvement, patient education, service
decentralization, HIV–TB collaboration, and research
[8,9]. However, most TB programs today continue to
function under a model of care that targets the proximal,
biomedical determinants of infection and maximizes TB
case detection, case notification, treatment adherence,
and cure [3,8,10].
HIV control, in contrast, has been rooted in a patient-
sensitive, individualized approach from its inception [3,6].
Clinical guidelines exist, but there is much less global
standardization of care, not unrelated to the rapid
evolution of scientific advancements and treatment access
[3,11]. While ‘case detection’ and adherence are
prioritized, HIV programs pay equal attention to patient
education, privacy, and empowerment, driven by
activism and an inherent mandate to safeguard individual
rights from the effects of stigma and discrimination
[12,13]. HIV programs traditionally support voluntary or
consensual testing as opposed to routine, in some cases
mandatory, TB screening [10,12,13]. The social deter-
minants of health, such as poverty and gender inequality,
are at the forefront of HIV management. This mindset,
although slowly emerging, remains comparatively infre-
quent within most TB programs.horized reproduction of this article is prohibited.
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disparate paradigms of care? In the early 1990s, when the
problem of co-infection emerged, social scientists noted
that the different approaches to HIVand TB management
were a product of their distinct clinical etiologies and
trajectories [5,6,12,13]. HIV is primarily transmitted
through intimate contact (e.g. sexual practices, needle
sharing), whereas TB is spread via airborne, nonintimate
contact (e.g. cough). Transmission of HIV, relative to TB,
involves more conscious behavioral pathways, notwith-
standing their shared social determinants. HIV prevention
therefore mandates working with patients, and the greater
involvement of people living with the virus is now
intrinsic to HIV policy and practice [14]. Enforced
compliance through collective government approaches or
medical coercion, as has been seen with TB management,
is perceived to be counterproductive to sustained
behavioral change [6,15].
HIV is also a lifelong, incurable illness with a persistent
infectious stage. TB may be rendered both noninfectious
and curable with 6–12 months of treatment. Relatively
authoritarian measures such as routine screening, treat-
ment supervision and, in some cases, mandatory
treatment may be easier to implement when a cure is
probable, as with TB, but difficult to sustain over a
lifetime, as with HIV [12,13]. The impact of stigma, often
more acutely experienced in cases of HIV, likely
reinforces the emphasis on patient privacy and con-
fidentiality within HIV programs [6]; consider the
different approaches of tracing and disclosing to TB
versus HIV ‘contacts’. Indeed, the HIV community’s
critique of policies that criminalize nondisclosure is
further testimony to their intolerance for collective
approaches that may compound HIV stigma and infringe
on individual patient rights [15].
Over the years, HIV and TB programs have attracted
diverse levels of social and political momentum.
Governments worldwide have less readily formed
consensus on the cause and impact of HIV, in part,
due to its association with behaviors perceived to be
immoral and illicit. As a result, early HIV programs met
fragmented political support and denialism in some cases
[16,17]. Affected communities rallied from the ground-
up to mobilize grassroots movements as a means to elicit
global consensus and a concerted response [14,16,17].
HIV activists, including persons living with HIV, were
and arguably remain some of the most powerful voices of
HIV resource mobilization [13,14,16]. HIVadvocacy was
also largely spearheaded by gay men, who were already
part of an established community [5,13]. TB advocacy has
lacked this populist grassroots support [14,16]. Instead,
TB programs have been criticized for alienating affected
communities through their top-down approach to disease
management. The lack of patient involvement in
decisions governing treatment access and adherence has
been tied to the absence of commensurate TB advocacypyright © Lippincott Williams & Wilkins. Unauthoand support worldwide [7,16]. Only recently have TB
practitioners started to reverse their longstanding use of
incriminating terms such as ‘suspects’ to describe people
affected by TB, which would be unthinkable to apply in
the context of HIV [18].
In comparison to HIV, operational and implementation
research for TB, including drug development, has
progressed at a much slower pace. Alongside an array
of antiretroviral agents, bedaqualine represents one of the
only truly novel antituberculosis agents to be approved in
decades [19]. The adoption of an unquestioning mindset
to established protocols has been argued to compound the
dearth of innovation in TB research [2,14]. Furthermore,
that HIV is recognized as an important public health
concern within many industrialized nations has armed
HIV programming with access to greater resources. The
impact of TB, on the contrary, remains concentrated
within poorer countries that have less monetary power to
initiate novel research or action [16].
HIVand TB programs thus appear to have become rooted
in diverse approaches to healthcare delivery. Yet, in our
quest for optimizing their concurrent management,
comparatively few studies have drawn attention to these
distinctions. In sharing their early experiences with
service integration in South Africa, Coetzee et al. [20] and
Friedland et al. [21] commented on the different
programmatic approaches within HIV and TB clinics.
Abdool Karim et al. [2] have suggested that the greater
attention to patient education and treatment literacy, and
address to the social implications of HIV, may help explain
the relatively higher rates of adherence and retention
recorded within some HIV programs. Indeed, the lack of
community empowerment, believed to be perpetuated
by a DOTapproach, has been associated with high rates of
patient attrition from TB clinics [8,16]. In KwaZulu
Natal province, we found co-infected patients’ com-
parative experiences within HIVand TB clinics not only
reflected the different ‘cultures’ of health care delivery
within HIVand TB programs, but additionally influenced
patients’ decisions for service integration [22]. The
impersonal attitude perceived within TB clinics, in
contrast to the compassion and privacy experienced
within HIV clinics, dissuaded some patients from
disclosing HIV to their TB and DOT providers and
from accessing dual services within the structure of a TB
program [22]. A recent study including patients co-
infected with HIV and drug-resistant TB found
adherence to antiretroviral therapy (ART) was signifi-
cantly higher than to second-line TB treatment [23]. In
related qualitative work, we analyzed how co-infected
patients’ dissatisfaction with TB services, characterized by
alienating experiences with TB notification and treat-
ment supervision, negatively influenced adherence to TB
treatment. By contrast, patients’ greater involvement in
HIV treatment and ARTeducation provided them with a
sense of ownership that reinforced preferential adherencerized reproduction of this article is prohibited.


































Fig. 1. Program collaboration amidst the contrasting cultures of HIV and tuberculosis care.to ART [24]. These data highlight how divergent models
of HIV and TB healthcare may influence patients’
decisions toward service integration and adherence,
which collectively may impact treatment outcomes for
co-infection.
In conclusion, we urge HIVand TB programs to address
their ‘cultural’ differences in framing collaborative efforts
(see Fig. 1), so that services may be delivered under a
cohesive and complementary approach that meets the
sociomedical needs of co-infected patients. Agencies such
as the WHO and United States Centres for Disease
Control are beginning to champion a public health
approach to HIV care, comprising stricter treatment
initiation criteria, standardized first-line and second-line
regimens, provider-initiated screening and testing with
opt-out mechanisms, and the application of DOT-based
models to ART [4,25,26]. Although these efforts reflect
some blurring of the differences between the two
programs, they have had to contend with the enduring
climate of HIV ‘exceptionalism’ [25], particularly around
treatment readiness and individualized consent to testing
and treatment. Commensurate efforts are needed around
the more widespread adoption of patient-sensitive
approaches to care within TB programs [4,15,16].
Realistic address to the distinct paradigms underlying
HIVand TB control must also consider how to marry the
holistic philosophy of HIV care with the focused strategy
of TB management in the context of available financial
and human assets.Acknowledgements
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